Interactions of MK-801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and behavioural sensitization

Behavioural Brain Research

Volumn 84, Issue 1-2, 1997, Pages 99-107

  Tzschentke, Thomas M ^a   Schmidt, Werner J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

amphetamine; conditioned place preference; glutamate receptor subtype; GYKI 52466; locomotion; MK 801; morphine; rearing; reward; sensitization

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; AMPHETAMINE; DIZOCILPINE; MORPHINE;

ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; CONTROLLED STUDY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIZATION;

EID: 0031047810     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(97)83329-3     Document Type: Article

References (49)

1. Babbini, M. and Davis, W.M., Time-dose relationships for locomotor activity effects of morphine after acute or repeated treatment, Br. J. Pharmacol., 46 (1972), 213-224.
2. Barr, G.A., Paredes, W. and Bridger, W.H., Place conditioning with morphine and phencyclidine: dose dependent effects, Life Sci., 36 (1985) 363-368.
3. Bespalov, A., Dumpis, M., Piotrovsky, L. and Zvartau, E., Excitatory amino acid receptor antagonist kynurenic acid attenuates rewarding potential of morphine, Eur. J. Pharmacol., 264 (1994) 233-239.
4. Bischoff, C. and Tiedtke, P.I., Competitive and non-competitive NMDA receptor antagonists in spatial learning tasks, Eur. J. Pharmacol., 213 (1992) 269-273.
5. Bozarth, M.A., Neuroanatomical boundaries of the reward-relevant opiate-receptor field in the ventral tegmental area as mapped by the conditioned place preference method in rats, Brain Res., 414 (1987) 77-84.
6. Bubser, M., Tzschentke, T.M. and Hauber, W., Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats, J. Neural Transm. [Gen. Sect.], 101 (1995) 115-126.
7. Cador, M., Bjijou, Y. and Stinus, L., Evidence of a complete independence of the neurobiological substrates for the induction and expression of behavioral sensitization to amphetamine, Neuroscience, 65 (1995) 385-395.
8. Carlezon Jr., W.A., Mendrek, A. and Wise, R.A., MK-801 disrupts the expression but not the development of bromocriptine sensitization: a state-dependency interpretation, Synapse, 20 (1995) 1-9.
9. Carr, G.D., Fibiger, H.C. and Phillips, A.G., Conditioned place preference as a measure of drug reward. In J.M. Liebman and S.J. Cooper (Eds.), The Neuropharmacological Basis of Reward, Clarendon Press, Oxford, 1989, pp. 264-319.
10. Cervo, L. and Samanin, R., Effects of dopaminergic and glutamatergic receptor antagonists on the acquisition and expression of cocaine conditioning place preference, Brain Res., 673 (1995) 242-250.
11. Colpaert, F.C., Amnesic trace locked into the benzodiazepine state of memory, Psychopharmacology, 102 (1990) 28-36.
12. Corbett, D., Possible abuse potential of the NMDA antagonist MK-801, Behav. Brain Res., 34 (1989) 239-246.
13. Cory-Slechta, D.A., The impact of NMDA receptor antagonists on learning and memory functions, Psychopharmacol. Bull., 30 (1994) 601-612.
14. Cox, J., Guthrie, R., Macrae, M. and Kehoe, E.J., MK801 impairs acquisition and expression of conditioned responses in the rabbit nictating membrane preparation, Psychobiology, 22 (1994) 156-166.
15. Cox, J. and Westbrook, R.F., The NMDA receptor antagonist MK-801 blocks acquisition and extinction of conditioned hypoalgesic responses in the rat, Quart. J. Exp. Psychol., 47B (1994) 187-210.
16. Dall Olio, R., Gandolfl, O. and Montanaro, N., Effect of chronic treatment with dizocilpine (MK-801) on the behavioral response to dopamine receptor agonists in the rat, Psychopharmacology, 107 (1992) 591-594.
17. Herberg, L.J. and Rose, I.C., The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain-stimulation reward, Psychopharmacology, 99 (1989) 87-90.
18. Hoffman, D.C., The use of place conditioning in studying the neuropharmacology of drug reinforcement, Brain Res. Bull., 23 (1989) 373-387.
19. Hoffman, D.C., The noncompetitive NMDA antagonist MK-801 fails to block amphetamine-induced place conditioning in rats, Pharmacol. Biochem. Behav., 47 (1994) 907-912.
20. Jackson, A., Koek, W. and Colpaert, F.C., NMDA antagonists make learning and recall state-dependent, Behav. Pharmacol., 3 (1992) 415-421.
21. Jeziorski, M., White, F.J. and Wolf, M.E., MK-801 prevents the development of behavioral sensitization during repeated morphine administration, Synapse, 16 (1994) 137-147.
22. Kalivas, P. W., Can EAA transmission play a ubiquitous role in drug-induced neural plasticity?, Behav. Pharmacol., 6 (1995), 452-454.
23. Kalivas, P.W. and Alesdatter, J.E., Involvement of N-methyl-D-aspartate receptor stimulation in the ventral tegmental area and amygdala in behavioral sensitization to cocaine, J. Pharmacol. Exp. Ther., 267 (1993) 486-495.
24. Kalivas, P.W. and Stewart, J., Dopamine transmission in the initiation and expression of drug-and stress-induced sensitization of motor activity, Brain Res. Rev., 16 (1991) 223-244.
25. Karcz-Kubicha, M. and Liljequist, S., Evidence for an anxiogenic action of AMPA receptor antagonists in the plus-maze test, Eur. J. Pharmacol., 279 (1995) 171-177.
26. Karler, R., Calder, L.D., Chaudhry, I.A. and Turkanis, S.A., Blockade of 'reverse tolerance' to cocaine and amphetamine by MK-801, Life Sci., 45 (1989) 599-606.
27. Karler, R., Calder, L.D. and Bedingfleld, J.B., Cocaine behavioral sensitization and the excitatory amino acids, Psychopharmacology, 115 (1994) 305-310.
28. Karler, R., Calder, L.D. and Turkanis, S.A., DNQX blockade of amphetamine behavioral sensitization, Brain Res., 552 (1991), 295-300.
29. Keseberg, U. and Schmidt, W.J., Low-dose challenge by the NMDA receptor antagonist dizocilpine exacerbates the spatial learning deficit in ntorhinal cortex-lesioned rats, Behav. Brain Res., 67 (1995) 255-261.
30. Koob, G.F., Drugs of abuse: anatomy, pharmacology and function of reward pathways, Trends Pharmacol. Sci., 13 (1992) 177-184.
31. Layer, R.T., Kaddis, F.G. and Wallace, L.J., The NMDA receptor antagonist MK-801 elicits conditioned place preference in rats, Pharmacol. Biochem. Behav., 44 (1993) 245-247.
32. 3H]D-AP5, Neuroscience, 30 (1989) 87-94.
33. Marek, P., Ben-Eliyahu, S., Vaccarino, A.L. and Liebeskind, J.C., Delayed application of MK-801 attenuates development of morphine tolerance in rats, Brain Res., 558 (1991) 163-165.
34. Morris, R.G.M., Anderson, E., Lynch, G.S. and Baudry, M., Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate antagonist, AP5, Nature, 319 (1986), 774-776.
35. Oles, R.J., Singh, L. and Tricklebank, M.D., Differential effects on the behavioural and anticonvulsant properties of MK-801 following repeated administration in the mouse, Br. J. Pharmacol., 99 (1990) 286P.
36. Papp, M. and Moryl, E., Rewarding properties of non-competitive and competitive NMDA antagonists as measured by place preference conditioning in rats, Pol. J. Pharmacol., 46 (1994) 79-81.
37. Perugmi, M. and Vezina, P., Amphetamine administered to the ventral tegmental area sensitizes rats to the locomotor effects of nucleus accumbens amphetamine, J. Pharmacol. Exp. Ther., 270 (1994) 690-696.
38. Phillips, A.G. and Fibiger, H.C., Anatomical and neurochemical substrates of drug reward determined by the conditioned place preference technique. In M.A. Bozarth (Ed.), Methods of Assessing the Reinforcing Properties of Abused Drugs, Springer, New York, 1987, pp. 275-290.
39. Spyraki, C., Fibiger, H.C. and Phillips, A.G., Dopaminergic substrates of amphetamine-induced place preference conditioning, Brain Res., 253 (1982) 185-193.
40. Spyraki, C., Nomikos, G.G. and Varonos, D.D., Intravenous cocaine-induced place preference: attenuation by haloperidol, Behav. Brain Res., 26 (1987) 57-62.
41. Sufka, K.J., Conditioned place preference paradigm: a novel approach for analgesic drug assessment against chronic pain, Pain, 58 (1994) 355-366.
42. Swedberg, M.D.B., Jacobsen, P. and Honore, T., Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo [f] quinoxaline (NBQX), J. Pharmacol. Exp. Ther., 274 (1995) 1113-1121.
43. Tzschentke, T.M. and Schmidt, W.J., N-Methyl-D-aspartic acid-receptor antagonists block morphine-induced conditioned place preference in rats, Neurosci. Lett., 193 (1995) 37-40.
44. Tzschentke, T.M. and Schmidt, W.J., Procedural examination of behavioural sensitisation to morphine: lack of blockade by MK-801, occurrence of sensitised sniffing, and evidence for cross-sensitisation between morphine and MK-801, Behav. Pharmacol., 7 (1996), 169-184.
45. Vasko, M.R. and Domino, E.F., Tolerance development to the biphasic effects of morphine on locomotor activity and brain acetylcholine in the rat, J. Pharmacol. Exp. Ther., 207 (1978), 848-858.
46. Wise, R.A., The brain and reward. In J.M. Liebman and S.J. Cooper (Eds.), The Neuropharmacological Basis of Reward, Clarendon Press, Oxford, 1989, pp. 377-424.
47. Wise, R.A. and Leeb, K., Psychomotor-stimulant sensitization: a unitary phenomenon?, Behav. Pharmacol., 4 (1993) 339-349.
48. Wolf, M.E. and Jeziorski, M., Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioral sensitization, Brain Res., 613 (1993) 291-294.
49. Wolf, M.E. and Khansa, M.R., Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine, Brain Res., 562 (1991) 164-168.